^
Association details:
| Biomarker: | EGFR mutation + CD73 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.
Published date:
05/16/2018
Excerpt:
In cohort B, the overall response rate of ICIs was significantly higher in patients with high CD73 expression than those with low CD73 expression (66.7% versus 0%, p= 0.006), and the high CD73 expression group showed significantly longer progression-free survival (PFS) than low CD73 group (median 16.0 months versus 1.2 months, p= 0.024)....In patients with EGFR mutation-positive NSCLC, expression of CD73 may predicts a favorable outcome of ICIs treatment unlike in EGFR mutation-negative patients.
DOI:
10.1200/JCO.2018.36.15_suppl.9065
